why choose us

First received: August 12, 2022

Clinical Trial: Atezolizumab for Idiopathic Pulmonary Fibrosis

Study Status: Completed

Recruit Status: RECRUITING

Condition: Idiopathic Pulmonary Fibrosis

Study Type: INTERVENTIONAL


Official Title: A Phase I Study to Evaluate the Safety and Preliminary Efficacy of Atezolizumab in Idiopathic Pulmonary Fibrosis

Brief Summary: The purpose of this study is to determine the safety and preliminary efficacy of atezolizumab, an immune checkpoint inhibitor approved for the treatment of various cancers, in patients with idiopathic pulmonary fibrosis (IPF).

Read more